Phase I Studies Drive 16% Rise In Danish Clinical Trial Applications
Clinical trial applications in Denmark rose by just under 16% in 2015, driven partly by a doubling in the number of Phase I studies, which the medicines agency attributes to the work of a new public-private partnership aimed at boosting Denmark’s attractiveness as a location for early-phase trials.
You may also be interested in...
Changes to the Danish clinical trials legislation will ensure that GCP inspectors, who were earlier denied direct access with their own username and password to electronic health records of trial subjects, now have full access to this information while inspecting studies.
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.